Assessment of female sexual arousal: Response specificity and construct validity

Specificity of vaginal pulse amplitude and vaginal blood volume in reaction to visual sexual stimuli was investigated by comparing responses to sexual, anxiety-inducing, sexually threatening, and neutral film excerpts. Subjective sexual arousal, body sensations, emotional experience, skin conductance, and heart rate were monitored along with the genital measures. Self-report data confirmed the generation of affective states as intended. Results demonstrated response specificity of vaginal vasocongestion to sexual stimuli. In terms of both convergent and divergent validity, vaginal pulse amplitude was the superior genital measure. Skin conductance discriminated among stimuli only to a small degree, whereas heart rate failed to discriminate among stimuli altogether.     

Effect of Steroid Eluting Versus Conventional Electrodes on Propafenone Induced Rise in Chronic Ventricular Pacing Threshold

The aim of this study was to evaluate chronic ventricular pacing threshold increase after oral propafenone therapy. Eighty-three patients affected by advanced atrioventricular hJock and sick sinus syndrome were studied at least 3 months after pacemaker implantation, before and after oral propafenone therapy (450–900 mg/day based on body weight). The patients were subdivided into three groups according to the type of unipolar electrode that was implanted: group I (41 patients)Medtronic CapSure 4003, group II(30 patients)Medtronic Target Tip 4011, and group III (12 patients)Osypka Vy screw-in lead. In all cases a Medtronic unipolar pacemaker was implanted: 30 Minix, 23 Activitrax, 14 Elite, 12 Legend, and 4 Pasys. Propafenone biood level was measured in 75 patients 3–5 hours after propafenone administration. The pacing autothreshoid was measured at 0.8 V, 1.6 V, and 2.5 V by reducing puise width. At the three different outputs before and after propafenone, threshold increments were significantly lower in group I in comparison with group II and group III (propafenone ranging from < 0.001 to < 0.05). No significant difference was found in pacing impedance or in propafenone plasma concentration in the three groups. Strength-duration curves were drawn for each group at baseline and after propafenone administration. Before propafenone, in group I, the knee was markedly shifted to the left and downward as compared to the classic curve, so that the steep part was predominant; in group II and group III this shift was progressively less evident. After propafenone we found the curve shifted to the right with the flat part progressively more evident in group II and group III as compared to group I. We conclude that steroid eiuting leads cause less threshold increase than conventionol and screw-in ones after oral propafenone, thus leading to safer chronic pacing. Chronic pacing at 2.5-V amplitude and 0.6-msec width was feasible in 97% of group I patients and in 80% of group II patients, but not in group III due to an insufficient safety margin. propafenone, pacing threshold     

Effect of the Superior Vena Cava Electrode Surface Area on Defibrillation Threshold in Different Lead Systems

Little data is available comparing the efficacy of the Transvene, Endotak C 70 series, and the active CAN configuration on defibrillation success. In addition, the impact of the superior vena cava (SVC) electrode surface area and length on the active CAN system is unknown. Therefore, we compared the defibrillation efficacy of the Transvene and Endotak C 70 series lead systems with and without the active CAN in dogs. Defibrillation threshold (DFT) testing was randomly performed in 20 dogs. In protocol I [10 dogs), DFT energy was compared in three BV/SVC lead systems with an SVC electrode defibrillating surface area of 90 mm² (Transvene-90), 160 mni² (Transvene-160). 617 mm² (En-dotak), and an RV/CAN configuration. In protocol II (10 dogs), DFT comparison was performed in the Transvene-90/CAN, Transvene-160/CAN. Endotak/CAN, and RV/CAN configurations. In protocol I, in-creasing the SVC surface area from 90 to 160 mm² and from 160 to 617 mm² significantly lowered DFT energy. The Endotak and the RV/CAN systems provided the lowest DET energy requirements. In protocol II, the Endotak/CAN system significantly lowered DFT energy compared to the other three lead configu-rations. In both protocols, the impedance decreased as the SVC surface area increased from 90 to 160 mm². However, no significant reduction in DFT impedance occurred as the SVC surface area increased from the Transvene-160 to the Endotak lead. Increasing the SVC surface area from 90 to 617 mm² in a two coil lead system lowered DFT energy to similar levels provided by the HV/CAN configuration. The addition of an SVC electrode with a surface area of 90 or 160 mm² did not reduce DFT energy compared to the RV/CAN configuration. The Endotak/CAN system, however, provided the lowest DFT requirements.     

Relationship Between Catheter Forces, Lesion Characteristics, "Popping," and Char Formation: Experience with Robotic Navigation System

Introduction: Popping, char and perforation are complications that can occur following catheter ablation. We measured the amount of grams (g) applied to the endocardium during ablation using a sensor incorporated in the long sheath of a robotic system. We evaluated the relationship between lesion formation, pressure, and the development of complications.
Methods: Using a robotic navigation system, lesions were placed in the left atrium (LA) at six settings, using a constant duration (40 seconds) and flow rate of either 17 cc/min or 30 cc/min with an open irrigated catheter (OIC). Evidence of complications was noted and lesion location recorded for later analysis at necropsy.
Results: Lesions using 30 Watts (W) were more likely to be transmural at higher (>40 g) than lower (<30 g) pressures (75% vs 25%, P < 0.001). Significantly higher number of lesions using >40 g of pressure demonstrated "popping" and crater formation as compared with lesions with 20–30 g of pressure (41% vs 15%, P = 0.008). A majority of lesions placed using higher power (45 W) with higher pressures (>40 g) were associated with char and crater formation (66.7%). No lesions using 10 g of pressure were transmural, regardless of the power. Lesions placed with a power setting less than 35 W were more likely to result in "relative" sparing of the endocardial surface than lesions at a power setting higher than 35 W (62% vs 33.3%, P = 0.02) regardless of the pressure.
Conclusions: When using an OIC, lower power settings (≤35 W) and lower/medium contact pressure were more likely to show a "relative" spared endocardial surface. Overall, contact pressure between 20 g and 30 g and a power setting of 40 W appeared to achieve transmurality by preserving safety.     

Efficacy of flecainide in pacing-induced sustained ventricular tachyarrhythmias: correlation to clinical parameters and tachycardia-characteristics

Seventy-two patients with sustained ventricular tachycardiaor syncope of unknown origin underwent electrophysiologic evaluationbefore and after therapy with flecainide (200–300 mg day^–1).In all patients, sustained ventricular tachycardia or ventricularfibrillation was inducible during control electrophysiologicstudy. During flecainide therapy, sustained ventricular tachycardia(VT) was no longer inducible in 18 patients (25%) whereas in54 patients, VT was still inducible. In five of the latter patients,VT became more difficult to induce (overall efficacy 32%). Therate of VT decreased from 214±49 beats min^–1 duringthe control electrophysiologic study to 178±48 beatsmin^–1 during flecainide (P<0.01). The ERP of the rightventricle increased from 251±27 ms during the controlstudy to 267±34 ms on flecainide (P<0.01). Mean ejectionfraction and mean LVEDP did not differ between responders andnon-responders, yet the presence of a left ventricular aneurysmcorrelated with a lack of antiarrhythmic response to flecainide.VT rate as well as VT morphology during the control study discriminatedbetween responders and non-responders; 11% of patients withVT-rate 230 beats min^–1 responded to oral flecainidecompared with 31% with a VT rate > 230 beats min^–1at control. 26% with induced monomorphic VT responded, comparedwith 100% with induced VF during the control study. 18 of 23responders were discharged on flecainide. During a mean follow-upof 26±18 months, two patients experienced a recurrenceof VT and in one patient, flecainide had to be discontinueddue to side-effects. Thus, the acute efficacy of flecainide, evaluated by serialdrug testing, correlates with haemodynamic parameters and thecharacteristics of tachycardia.     

Clinical Experience with Orthocor II Antitachycardia Pacing System for Recurrent Tachyarrhythmia Termination

Between June 1986 and December 1988, eight patients were treated with an Orthocor II 284 A antitachycardia pacemaker (Cordis Corp., Miami, FL, USA) forsupraventricular tachycardia (SVT) and ventricular tachycardia (VT) termination. Four patients had intra-AV nodal reentrant tachycardias; 1 patient had AV reentrant tachycardia with an atrio-nodal accessory bypass tract; 2 patients had AV reentrant tachycardias with concealed Kent bundle, and 1 patient had ventricular tachycardia. All patients had been treated with three or more drugs and were considered to be drug refractory. The programmed antitachycardia mechanism used for patients with SVT were: automatic overdrive in five patients and burst scanning in two patients. In the patient with VT, a critically timed double extrastimulus with fixed coupling interval was programmed. Follow-up ranged from 2 to 30 months. The pacemaker proved to be effective in terminating tachycardias in all cases with SVT; in the patient with VT, the programmed antitachycardia mechanism was effective for a long time, but after an episode of sustained VT not interrupted by the pacemaker, the patient underwent automatic cardioverter/defibrillator (AICD) implantation. Additional antiarrhythmic therapy was required in 3 patients to control their maximum sinus rate, in 1 patient to reduce tachycardia episodes and to enable termination, and in 2 patients to prevent spontaneous atrial fibrillation. It is concluded that Orthocor II is a flexible and versatile antitachycardia pacemaker providing a safe and effective control of recurrent tachycardia in selected patients.     

Mechanisms of Late Stent Malapposition After Primary Stenting in ST-Elevation Myocardial Infarction: A Subanalysis of the Selection Trial

Background: One of the major predictors of late stent malapposition (LSM) is primary stenting in acute myocardial infarction. However, mechanisms of LSM are still under debate.
Methods: Patients with ST-elevation myocardial infarction (STEMI) and enrolled in the SELECTION trial (38 patients in the paclitaxel-eluting stent, PES, and 35 in the bare metal stent, BMS, cohort) were retrospectively analyzed to evaluate LSM, by means of intravascular ultrasound (IVUS) data recorded at the index and 7-month follow-up procedures.
Results: Stent malapposition was documented in 21 lesions in 21 patients (28.8%): in 8 of these 21 patients (38.1%) it was LSM. Although statistical significance was not reached, LSM was more frequent after PES than BMS implantation (15.8% vs. 5.7%). LSM was mainly located within the body of the stent (62.5% of the cases). At the LSM segment, a significant increase of vessel area (19.2 ± 3.3 mm² vs. 21.9 ± 5.3 mm², P = 0.04) and a reduction of plaque area (12.6 ± 4.6 mm² vs. 9.1 ± 3.9 mm², P = 0.04) were observed at IVUS between the index and follow-up procedure.
Conclusions: After primary stenting for STEMI, LSM seems to be more frequent after PES rather than BMS implantation. In the STEMI setting, possible mechanisms leading to LSM include positive remodeling and plaque mass decrease.     

Experience with Two Different Nonthoracotomy Systems for Implantable Defibrillator in 170 Patients

Implantation of a nonthoracotomy system (Medtronic PCD or CPI Endotak) was attempted in 170 patients with ventricular tachycardia (VT) or ventricular fibrillation (VF) not requiring concomitant cardiac surgery. A nonthoracotomy system could be successfully implanted in 95 of the 115 patients with the PCD system and 49 of 55 patients receiving the Endotak lead system. In 26 patients with failed nontboracotomy system because of defibrillation threshold (DFT) > 25 joules (J), an epicardial system was implanted at the same setting. Patients receiving the two lead systems were comparable with regard to age, sex, and ejection fraction. However, since tbe PCD system offers tiered therapy multiprogrammable options, all attempts were made to implant tbis lead system in patients with VT that could be pace terminated. Mean DFT(15 ± 4.7 vs 17 ± 4.6 J;P = 0.03) and implant time (2.5 ± 0.6 vs 3.3 ± 0.7 hours; P = 0.02) were less with the Endotak lead system. There was no perioperative mortality. During a mean follow-up of 20 ± 4 months, there were eight instances of lead dislodgment in patients receiving the PCD system. Tbere were four nonsudden cardiac deaths and one sudden death in the Endotak group and three nonsudden deaths in the PCD group. Sudden cardiac death and total survival using the intention-to-treat analysis during this follow-up period were 99% and 95%, respectively. In conclusion, successful implantation, perioperative mortality, and survival rate are comparable with both lead systems; however, incorporating two defibrillating electrodes in one lead minimizes lead dislodgment and reduces implant time.